News

Eric Rios-Doria, MD, and colleagues compared treatment recommendations for patients with gynecologic cancers made by ChatGPT vs a multidisciplinary tumor board.

Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.

Efforts to streamline and improve the integration of germline testing for patients with ovarian cancer have seen significant success with the implementation of an integrated clinical pathway dashboard at Kaiser Permanente in Northern...

Ranjit Manchada, PhD, and colleagues analyzed the cost-effectiveness of prevention strategies for ovarian cancer and breast cancer risk reduction for individuals who carry cancer susceptibility genes.

A recent study examined the effects of an individualized starting dose of niraparib on hematologic adverse events in patients with advanced ovarian cancer.

Artificial intelligence machine learning models have shown promising results in predicting the outcomes of epithelial ovarian cancer according to a recent study presented at the 2024 SGO Annual Meeting on Women’s Cancer.

According to a phase 3 trial, the addition of induction chemotherapy prior to chemoradiation improved the progression-free survival and overall survival among patients locally advanced cervical cancer.

According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...

According to results from a phase 3 trial presented at the 2024 SGO Annual Meeting on Women’s Cancer, the addition of atezolizumab to first-line bevacizumab and chemotherapy improved progression-free survival, overall survival, and objective...

Tisotumab vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate among patients with second-/third-line recurrent or metastatic...